International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP)

IJRPP |Vol.14 | Issue 2 | Apr - Jun -2025

www.ijrpp.com

ISSN: 2278-2648

DOI : https://doi.org/10.61096/ijrpp.v14.iss2.2025.423-432

Review/Research

Stone Man Syndrome: Unraveling The Layers of A Rare Genetic Disorder

Shaik Parveen, Gutha. Sisira Pushpa*, Banothu. Anusha, Goggela. Rajini

Malla Reddy College of Pharmacy, Maisammaguda, Dhulapally, kompally [Post], Secunderabad-500100, India

*Author for Correspondence: Gutha. Sisira Pushpa
Email: sisiragutta@gmail.com

Published on: 11 Jun 2025

Published by:
DrSriram Publications

Abstract

Progressive heterotopic ossification [HO] of soft connective tissues, such as muscles, tendons, and ligaments, is a hallmark of fibrodysplasia ossificans progressiva [FOP], popularly known as "Stone Man Syndrome," an incredibly rare autosomal dominant genetic condition. A gain-of-function mutation in the activin A receptor type 1 [ACVR1] gene, most frequently R206H, induces constitutive activation of the bone morphogenetic protein [BMP] signaling pathway, even in the absence of ligands, leading to this crippling illness. Congenital abnormalities of the great toes are the usual early childhood manifestation of FOP, frequently occurring before flare-ups that result in progressive immobility and disability. Clinical presentation, radiologic imaging, and confirming genetic tests are all necessary for the diagnosis. The condition is often misdiagnosed due to its rarity and complexity, which delays necessary early care. No curative therapy currently exists; management focuses on minimizing trauma, avoiding intramuscular procedures, and controlling flare-ups with corticosteroids. Surgical intervention is limited to select cases and must be approached with caution due to risk of further ossification. Ongoing research into ACVR1 inhibition and BMP pathway modulation holds promise for disease-modifying treatments. This review aims to consolidate current understanding of FOP's genetic basis, clinical presentation, diagnostic approach, and evolving management strategies to improve outcomes in this challenging and life-limiting disorder.

Keywords: Fibrodysplasia ossificans progressiva, activin A receptor type 1, bone morphogenetic protein, corticosteroids, heterotopic ossification.

INTRODUCTION

Fibrodysplasia ossificans progressiva [FOP] was the same rare condition which causes the body to grow bone where it shouldn't. It is also known as "Stone Man Syndrome," "Bone Man Disorder," or Munchmeyer sickness [1]. In FOP, soft tissues including muscles and tendons progressively change into bone. During this phase, the body essentially "locks up" and the person appears to be turning into stone [1, 3]. The nickname "Stone Man" was coined in 1648 when French surgeon Guy Patin first described a patient who had the condition. Muscle as well as the connective tissue can become bone due to this genetic condition which is extremely rare, which impacts one out of every two million people. It has an autosomal dominant pattern and starts in childhood.

Trauma-induced flare-ups result in excruciating calcified masses. In 2006, the gene [ACVR1] was discovered. Shorter or fused digits are examples of physical symptoms. Although there isn't a cure, ACVR1 signaling may be the focus of future therapies [2]. Although there are several ideas that relate FOP to the HLA-B27 gene [which is associated to ankylosing spondylitis], genetic screening of 23 FOP patients showed the allele in only 9% of cases, which is equivalent to the general population. This suggests that FOP is not associated with HLA-B27 and that its pathophysiology differs from that of other HLA-B27-related illnesses [3]. An uncommon genetic condition which is known as fibrodysplasia [myositis] ossificans progressiva [FOP] causes the muscles and connective tissue to gradually ossify, causing discomfort and impairment [4,5]. There have been about 700 instances documented, and the frequency is roughly 1 in 2 million. There have been no reports of racial, ethnic, or sexual bias [6]. FOP typically manifests as a complete penetrance and autosomal dominant trait during the first ten years of life [7,8,9] built the FOP gene finding in 2006.

Guy Patin originally referred to this condition as "stone man" in 1648, and it can result in total ossification of the muscular system [9,10]. A painful inflammatory mass that eventually calcifies may form as a result of trauma to a particular area of the body. Due to the possibility of masseter or pterygoid muscle calcification, which would restrict jaw motion, even dental surgery could be a dangerous procedure. Microdactyly, finger hypoplasia and fusion, shorter metatarsal and metacarpal bones, and microdactyly of the thumb and toe are further anomalies [11]. FOP does not have an effective treatment [4,12]. Future therapies that inhibit activin A receptor type 1 [ACVR1], often referred to as activin receptor-like kinase 2 [ALK2] signaling, may serve as the foundation for treating FOP [12].

Background

The progressive soft tissues replacement including muscles, tendons, as well as ligaments with bone was a hallmark of Stone Man syndrome, a disorder that limits movement and can result in severe impairment. The goal of the Stone Man syndrome study article is to present an extensive overview of the state of our understanding on the disorder's etiology, genetics, and clinical characteristics. The diagnostic standards and available treatments for patients with FOP will also be covered in this article. To give a thorough picture of the state of FOP research today, the study will consult a variety of sources, such as case reports, medical databases, and published literature. To give a thorough picture of the state of FOP research today, the study will consult a variety of sources, such as case reports, medical databases, and published literature. Clinicians, researchers, patients with the condition, and their families will all find the article interesting. This study article's ultimate purpose is to advance our knowledge of Stone Man syndrome and enhance the diagnosis and management of this crippling ailment [13].

Etiology

The majority of stone man syndrome [FOP] instances happen seldom. With complete gene penetration, human stone syndrome is inherited in the dominant autosomal pattern. A genetic mutation was present in the ACVR1 gene, which was found on chromosome 2's long arm as 2q24.1, causes Stoneman syndrome [FOP]. It contributes to the signaling cascade of the BMP receptor, which controls the destiny of stem cells. Human BMPR receptors comprise BMPR1A, BMPR1B, BMPR2, and BMP4, and only BMPR1A and BMP4 receptors have significant functions in the FOP signaling pathway. The bone marrow precursor receptor protein [BMP], which encodes the BMPR1A receptor, is encoded by the ACVR1 gene [14]. The long arm of chromosome 10as 10q23.2 contains the BMPR1A gene. At codon 206 of the ACVR1 protein, arginine amino acids are substituted for histidine due to a mutation which was in the ACVR1 gene. Because of this amino acid alteration, ACVR1 is abnormally activated, changing connective tissue and causing muscle tissue to become the secondary skeleton. The endothelial cells eventually undergo this process to become mesenchymal stem cells, which then develop into bone [15].

It should be mentioned that the majority of instances of Stoneman Syndrome [FOP] are brought on by spontaneous mutations in gametes. Additionally, because FOP is inherited autosomally dominantly, FOP can develop with just one copy of the ACVR1 mutant gene. The spontaneous mutation in the gametes is the primary reason of the altered gene's ability to be passed down from one parent to the following generation. Additionally, environmental epigenetic influences can cause gene mutations, including microbiological bodies [bacteria, viruses, maternal nerve shock during zigzag cell failure], starvation, bad lifestyle, bio-contaminated ecosystems,

and excessive and uncontrolled drug usage ACVR 1 plays a part. However, it is still unknown what specifically causes the human stone syndrome and why the mutation in the ACVR1 gene occurs spontaneously [16].

Epidemiology

As of 2017, there were only about 800 verified cases of FOP worldwide, making it an extremely rare condition. Because of its rarity, FOP is regarded as one of the rarest illnesses that humans have ever encountered. With an estimated frequency of 0.5 occurrences per million, FOP affects people of all ethnicities despite its low prevalence. It's crucial to remember that these figures are still up to date and applicable today [17].

Causes

A mutation in the ACVR1 gene, which codes for the production of type 1 receptors that react to the protein BMP present in muscles and cartilage, is the cause of FOP. Bone and muscle growth and development are regulated by BMP. The ACVR1 mutation causes the receptor to be perpetually active in people with FOP, much like an inoperable light switch [18]. Because FOP is inherited in an autosomal dominant form, a child can be affected by the condition if only one parent passes on the mutated gene to them. If one parent carries the FOP gene, the child has a 50% chance of inheriting the disorder. The majority of FOP cases are brought on by a novel mutation in the ACVR1 gene, or de novo, which does not always occur in the family tree. These mutations happen at random [19].

Pathophysiology

A heterozygous missense mutation in the ACVR1 gene, commonly referred to as ALK2, which codes for a type I receptor in the bone morphogenetic protein [BMP] signaling pathway, is the primary cause of the rare autosomal dominant condition known as fibrodysplasia ossificans progressiva [FOP]. At codon 206 of the ACVR1 protein, the most prevalent mutation, R206H, causes histidine to be substituted for arginine. Although FOP can be inherited, de novo mutations cause the majority of instances to occur randomly [20]. The TGF-β superfamily includes the serine/threonine kinase receptor ACVR1. Under typical circumstances, ACVR1 participates in BMP signaling, which controls important developmental processes such the creation of muscles and bones. Type II receptors phosphorylate type I receptors [such as ACVR1] upon ligand binding [e.g., BMPs], and these receptors phosphorylate receptor-regulated SMAD proteins [R-SMADs: SMAD1, SMAD5, SMAD8]. To control the expression of genes involved in osteogenesis and tissue differentiation, these activated R-SMADs translocate to the nucleus and form complexes with co-SMAD [SMAD4][21]. The R206H mutation causes the BMP pathway to be activated in FOP without the need for a ligand. Even when BMPs are not present, this results in constitutive activation of SMAD1/5/8 signaling. The aberrant responsiveness to Activin-A, a ligand that typically activates SMAD2/3, represents a significant aberration. Instead, because of the mutant ACVR1 receptor, Activin-A in FOP improperly initiates SMAD1/5/8 activation, which promotes endochondral ossification and chondrogenesis in soft tissues [22].

Connective tissue and skeletal muscle gradually change into heterotopic bone as a result of this aberrant signaling; this process resembles normal skeletal development but takes place ectopically. Under the impact of dysregulated BMP signaling, mesenchymal progenitor cells differentiate into chondrocytes and osteoblasts, causing the endothelial-to-mesenchymal transition. As a result, a secondary skeleton forms, which significantly impairs movement and increases morbidity. Furthermore, the increased signaling in FOP may be too strong for inhibitory SMADs [SMAD6/7], which typically control the level of ACVR1 activity by competing with SMAD4. Unchecked osteogenic gene expression is further facilitated by structural alterations in the receptor complex and downstream transcriptional machinery [23,24]. Finally, the mutation results in a persistent, gradual, and irreversible ossification of soft tissues, which is frequently brought on by invasive operations, inflammation, or trauma. This highlights how important ACVR1 is for preserving tissue homeostasis. Figure 1 illustrates, A gain-of-function mutation in the ACVR1 (ALK2) gene is responsible for the pathophysiology of FOP, which results in abnormal osteogenic gene expression and ligand-independent activation of BMP signaling.



Fig 1: Mechanism of aberrant bone formation in FOP demonstrating downstream osteogenic signaling and BMP pathway activation caused by ACVR1 mutation.

Symptoms

The rare and highly incapacitating hereditary illness known as fibrodysplasia ossificans progressiva [FOP], or Stone Man Syndrome, is typified by progressive heterotopic ossification [HO], in which soft tissues like muscles, tendons, and ligaments are progressively replaced by bone. Big toe deformity is one of the first and most common congenital characteristics seen in all people with FOP. About 10% of those who are impacted may also have thumb deformities [25]. Stone Man Syndrome exhibits an age-dependent clinical progression, starting with congenital toe malformations and advancing through early flare-ups, joint immobility, and thoracic involvement, ultimately resulting in severe cardiopulmonary complications by adulthood in Figure 2. These skeletal abnormalities are frequently noticeable from birth and act as early indicators for diagnosis.

Other common congenital abnormalities consist of:

- Great toes that are shortened or deformed
- Fifth toe curvature
- Thigh bone abnormalities or short femoral necks
- Abnormalities of the cervical spine, including short necks and deformed vertebrae

In FOP, abnormal bone development typically starts in early childhood and frequently happens after intramuscular injections, viral infections, or soft tissue injuries. Ectopic bone growth typically develops on its own in:

- Tendons
- Ligaments
- The skeletal muscles
- Connective tissues and fascia

A low-grade fever may accompany the initial symptoms, which include soft tissue stiffness, edema, and localized discomfort. The neck, shoulders, back, chest, arms, and legs are the first areas that are frequently impacted [26].

The disease's progression frequently results in:

- Limited mobility of the joints Speech and swallowing difficulties brought on by jaw and neck involvement development of kyphosis or scoliosis,
- two spinal abnormalities,
- Walking difficulties,
- decreased mobility,
- ultimately immobility

Heterotopic bone development can compress lymphatic channels and blood arteries in more severe situations, resulting in:

- Complications with the arteries,
- Obstruction of lymphatic flow,
- Potentially fatal flare-ups

Nearly 50% of people with FOP have also been found to have hearing impairment, which may be brought on by aberrant ossification of the middle ear bones.

As the thoracic cage gets smaller, respiratory problems might occur, which can lead to:

- decreased lung capacity,
- recurring infections of the respiratory system,
- Breathlessness

Additionally, even during everyday activities like walking, people may be at risk for bone fractures, particularly in areas of aberrant ossification like the skull or pelvis [27].



Fig 2: Clinical progression of Stone Man Syndrome by age, emphasizing key manifestations, characteristic features, and complications at various life stages.

Diagnosis

Heterotopic ossification [HO] of connective tissues progresses in fibrodysplasia ossificans progressiva [FOP], a rare and very incapacitating hereditary condition. As of yet, there is no cure or treatment that can stop the sickness. Preventing invasive operations that could hasten the evolution of the disease and minimizing long-term damage depend on early clinical identification [28]. Stone Man Syndrome is diagnosed through a mix of clinical assessments, radiological imaging, genetic testing, and functional evaluations. Hallmark features like malformed great toes and ACVR1 gene mutations are crucial diagnostic indicators which is illustrated in Fig 3.

a) Indicators of Early Clinical features

Early diagnosis is made possible by congenital anomalies of the great toes, which frequently give rise to initial clinical suspicion. Early detection of these digital abnormalities offers a critical window for timely management to avoid detrimental interventions later in life [29].

b) Radiological Evaluation

Imaging tests are essential for both diagnosing and tracking FOP over time. Bilateral hallux valgus or monophalangism of the great toes, as well as linear or sheet-like heterotopic bone in distinctive distributions, are commonly seen on plain radiographs. Computed tomography [CT] and other advanced imaging techniques allow for thorough three-dimensional mapping of ectopic ossification and help assess joint involvement and disease progression [30].

c) Verification via Molecular Genetics

Molecular genetic testing is necessary for a conclusive diagnosis of FOP. The diagnosis is supported by mutational study of the ACVR1 gene, specifically the discovery of the recurrent R206H mutation. Genetic testing helps avoid needless invasive procedures that can worsen a disease and is particularly useful in atypical or unclear clinical presentations [31].

d) Laboratory Studies

Routine biochemical tests are usually unimpressive, but flare-ups may cause a slight increase in erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]. Urinary levels of basic fibroblast growth factor may rise during the angiogenic phase of lesion development, while serum alkaline phosphatase may rise during active ossification. Genetic testing is used to confirm a definitive diagnosis, usually detecting the recurrent R206H mutation in the ACVR1 gene [32].

e) Features of Imaging

The following radiographic findings support FOP:

- Ectopic ossification in the abdominal, chest, and neck soft tissues
- Hallux valgus deformity on both sides
- Unilingual great toes
- pseudo-exostoses on the tibiae's medial surfaces

- First metacarpals and metatarsals that are short
- C2–C7 facet joint fusion
- Larger components of the posterior vertebrae
- Tall and narrow vertebral bodies
- Femoral necks are broad and short

f) Distinctive Diagnosis

Due to its rarity and clinical comorbidity with diseases such lymphedema, dermatomyositis, juvenile fibromatosis, and soft tissue sarcoma, FOP is frequently misdiagnosed. Additionally, it needs to be differentiated from progressive osseous heteroplasia [POH], another genetic HO condition that usually starts with cutaneous ossification and does not exhibit digital abnormalities. The prevalence of toe deformities, distinctive flare-ups, and the lack of cutaneous abnormalities distinguish FOP from POH [33].

g) Diagnostic Errors

Many times, FOP is misdiagnosed, which results in needless biopsies or surgeries that cause iatrogenic injury. Because of the condition's rarity and inconsistent early symptoms, delayed diagnosis is usual. Early and accurate diagnosis depends on a combination of established diagnostic techniques and increased knowledge of traditional clinical and radiographic findings [34].

h) New Biomarkers in Development

Potential biomarkers that can make illness monitoring and treatment evaluation easier are being looked into in recent studies. There is potential for future clinical application as elevated levels of certain pro-inflammatory cytokines and cartilage matrix proteins are being investigated as markers of disease activity and progression [35].

i) Considerations for Prenatal Diagnostics

Prenatal genetic screening allows for early diagnosis in families with a known history of FOP mutations [36]. To address the ethical concerns and support well-informed decision-making, comprehensive genetic counseling must be provided in conjunction with such testing.

j) Methods of Therapy and Supportive Care

FOP results from gain-of-function mutations in the ACVR1/ALK2 receptor, which cause aberrant overactivation of bone morphogenetic protein [BMP] signaling, especially BMP-4. Through fibroproliferative and inflammatory processes, this leads to the development of ectopic bone.

Treatment is still supportive at the moment, with the goal of reducing trauma and triggers for flare-ups. It is crucial to refrain from iatrogenic procedures such as biopsies and intramuscular injections. Acute flare-ups affecting the jaw, major joints, or submandibular areas are treated with corticosteroids as the first line of treatment. Within 24 hours of the flare-onset, a 4-day course of high-dose prednisone [2 mg/kg/day] may help reduce edema and inflammation. It is advised to taper off corticosteroid courses gradually if more are required. Since it might be challenging to determine the onset and duration of flare-ups in the back, trunk, or neck, corticosteroids are not usually advised for these conditions [37].

k) Recovery and Preventive Actions

Reducing the risk of trauma and falls in children is essential. Restricting physically dangerous play, wearing protective gear, enhancing home safety, and changing activities are examples of preventive measures. The goals of rehabilitation are to avoid passive range-of-motion exercises that could trigger flare-ups and to maintain function through occupational therapy. Adaptive techniques and vocational training promote self-sufficiency and well-being [38].



Fig 3: Diagnostic criteria and evaluation methods for Stone Man Syndrome, emphasizing key and secondary indicators in clinical, radiological, genetic, and functional areas.

Treatment and management

I. Strategies for Prevention

Preventing flare-ups and the difficulties they cause is the main goal of FOP care. The focus of preventative care is on rigorously avoiding physical stress, which includes abstaining from activities that cause severe muscle tension, invasive dental operations without appropriate precautions, and intramuscular injections. Reducing falls and soft tissue injuries requires environmental adjustments, such as the use of protective gear and house safety changes [39].

II. Management of Pharmacology

a) Handling Severe Flares

Glucocorticoids continue to be the mainstay of treatment for acute flare-ups. In order to reduce inflammation and prevent the development of heterotopic ossification, a brief course of high-dose prednisone should ideally be started within the first 24 hours of symptom onset. Non-steroidal anti-inflammatory medications [NSAIDs] can provide pain management and symptomatic alleviation for milder attacks [40].

b) Treatments that Modify Disease

Targeted therapies that target the molecular basis of FOP have been made available by recent therapeutic advancements. Notably, the FDA has approved the use of palovarotene [SOHONOS], a selective retinoic acid receptor gamma [RAR-γ] agonist, in patients 14 years of age and older. As the first disease-modifying treatment authorized for FOP, this drug has proven effective in decreasing heterotopic bone growth, which is a noteworthy milestone [41].

c) Clinical Research

Clinical studies are now being conducted to evaluate a number of novel medicines, including:
Anti-inflammatory drugs that target particular fibro genic and inflammatory pathwaysACVR1/ALK2 receptor inhibitors to control dysregulated BMP signaling techniques using stem cells to stop ectopic ossification [42].

d) Assistance for the Respiratory System

A key element of FOP care is respiratory control because of the gradual reduction of thoracic movement. In order to maintain lung function and reduce consequences, routine pulmonary function evaluations and prompt respiratory interventions such as chest physical therapy and assisted breathing during respiratory illness are essential [43].

e) Management of Nutrition

Maintaining dietary sufficiency becomes more difficult when the condition worsens and jaw ankylosis appears. To avoid malnutrition and lower the risk of aspiration, dietitian-led treatments that emphasize safe feeding practices and soft-texture meals are crucial [44].

f) Occupational and Physical Therapy

Programs for physical therapy that are tailored to the individual enable functional preservation. The goal of activity planning is to prevent movements that could cause flare-ups while preserving freedom in day-to-day living. Occupational therapy and adaptive technologies allow people to safely participate in everyday activities without endangering delicate tissues [45].

g) Handling Pain

Pain management calls for a customized, multimodal strategy that combines non-pharmacologic tactics like cognitive behavioral therapy or relaxation techniques with pharmaceutical treatments like acetaminophen, NSAIDs, or opioids. To maximize patient comfort and quality of life, treatment regimens must be continuously monitored and adjusted [46].

III. Psychosocial and Multidisciplinary Care

a) Model of Integrated Care

A cooperative, multidisciplinary strategy combining rheumatologists, orthopedists, pulmonologists, physiatrists, and genetic counselors is necessary for the best treatment of FOP patients. Managing patients' complex and changing needs requires healthcare providers to coordinate care and communicate consistently [47].

b) Emotional and Psychological Assistance

FOP's chronic, progressive, and incapacitating character can have a major effect on mental health. Promoting emotional resilience in patients and caregivers requires psychosocial interventions, such as access to support groups and professional counseling [48].

c) Being Ready for Emergencies

Individualized emergency treatment plans should be provided to patients due to the possibility of iatrogenic injury. In order to prevent actions that can cause flare-ups or worsen the illness, healthcare professionals particularly those working in emergency situations need to be trained on FOP-specific

safety measures [49]. Addressing Stone Man Syndrome in Figure 4, requires a multidisciplinary strategy that encompasses preventive care, timely glucocorticoid treatment during flare-ups, chronic use of FDA-approved medications such as palovarotene, supportive therapies, and emergency protocols specifically designed to prevent exacerbation.



Fig 4: Treatment strategies for Stone Man Syndrome categorized by care type, intervention timing, and associated contraindications.

CONCLUSION

About 1 in 2 million people worldwide have fibrodysplasia ossificans progressiva [FOP], one of the rarest and most incapacitating hereditary illnesses known to medicine. Progressive ossification of soft tissues, the disease's defining feature, causes progressive and irreversible functional loss that significantly lowers quality of life. Mutations in the ACVR1 gene cause the pathophysiology of FOP by inappropriately activating the BMP signaling system, specifically the SMAD1/5/8 axis, as this review has shown. Through an endochondral ossification mechanism, soft tissues are abnormally transformed into bone, creating a "second skeleton." Effective management of FOP depends on early detection. Hallux valgus and monophalangism, two congenital deformities of the great toes, are trustworthy early clinical markers. It's critical to steer clear of intrusive diagnostic or treatment procedures that can cause flare-ups. While molecular genetic testing provides a conclusive diagnosis, imaging particularly MRI and CT helps with early detection and illness progression monitoring.

The majority of management is still preventative and supportive. Early flare-ups may benefit from the use of corticosteroids to reduce inflammation, especially when the jaw or major joints are affected. To maintain function and autonomy, long-term strategies include fall prevention, trauma avoidance, and thorough recovery. Only after ossification has stabilized and the risks of aggravation are low can surgical procedures be explored, as they are rarely justified. Though there is currently no cure, there is hope due to recent developments in our knowledge of the molecular underpinnings of FOP. Targeted treatments that block abnormal ACVR1 signaling or alter the activity of the BMP pathway are being researched. In the near future, these might provide the first real disease-modifying alternatives. Additionally, ectopic ossification may be prevented or reversed by clinical trials and new biologics that target osteogenic pathways or inflammatory mediators. Care that is multidisciplinary is crucial. Patients benefit from tailored treatment regimens, physical and occupational therapy, and psychological support in addition to clinical monitoring. It is impossible to overestimate the importance of education for both patients and healthcare professionals. Due to ignorance, many instances are misdiagnosed or inadequately handled, leading to needless treatments and quick progression.

On conclusion, FOP is a terrible genetic illness that is becoming more recognized. There is optimism for better management and future advancements due to the identification of its genetic foundations, enhanced diagnostic procedures, and expanding therapeutic research pipeline. The most effective way to manage this complicated problem at the moment is to combine genetic counseling, trauma prevention, close clinical monitoring, and clinical research participation. To convert molecular insights into observable patient results, sustained international cooperation and research funding are crucial.

REFERENCES

1. Bridges AJ, Hsu KC, Singh A, Churchill R, Miles J. Fibrodysplasia [Myositis] ossificans progressiva. Seminars in Arthritis and Rheumatism. 1994;24[3]:155–164. doi: 10.1016/0049-0172[94]90071-X.
2. Calvert GT, Shore EM. Human leukocyte antigen B27 allele is not correlated with fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1998;[346]:66–70.
3. "Medical Definition of fibrodysplasia ossificans progressiva". www.merriam-webster.com. Retrieved 8 May 2022. Pinkowski, Jen [1 March 2019]. "Here's what happens when your body tissues turn to bone". National Geographic. Archived from the original on 3 March 2019.
4. Kim JT, Yoon YH, Baek WK, Han JY, Chu YC, Kim HJ. Myositis ossificans of the chest wall simulating malignant neoplasm. Ann of Thorac Surg. 2000;70[5]:1718–1720.
5. Orhan K, Uyanik LO, Erkmen E, Kilinc Y. Unusually severe limitation of the jaw attributable to fibrodysplasia ossificans progressiva: a case report with cone-beam computed tomography findings. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113[3]:404–409.
6. Lucotte G, Bathelier C, Mercier G, Gerard N, Lenoir G, Semonin O, et al. Localization of the gene for fibrodysplasia ossificans progressiva [FOP] to chromosome 17q21-22. Genet Couns. 2000;11[4]:329–334.
7. Xu MQ, Shore EM, Kaplan FS. Reported noggin mutations are PCR errors. Am J Med Genet. 2002;109[2]:161–163. doi: 10.1002/ajmg.10288. Stark William H, Krechel Susan W, Eggers Jr GWN. Anesthesia in ‘stone man’: Myositis ossif icans progressiva. J Clin Anes. 1990;2[5]:332–335.
8. Thickman D, Bonakdar-pour A, Clancy M, Van Orden J, Steel H. Fibrodysplasia ossificans progressiva. AJR Am J Roentgenol. 1982;139[5]:935–941.
9. Kaplan FS, Shore EM, Glaser DL. The medical management of fibrodysplasia ossificans current treatment consideration. Clin Proc intl clin consort FOP. 2005;1:1–71.
10. McCullough, Marie [28 February 2019]. "New Mutter Museum exhibit grants final wish for woman who turned to bone". The Philadelphia Inquirer. Retrieved 28 February 2019.
11. "Mütter Museum Reveals New Exhibit: Philadelphia Woman's Skeleton With Rare Bone Disease". Mütter Museum. 5 March 2019. Archived from the original on 28 August 2021. Retrieved 7 March 2020
12. Genetics Home Reference, U.S. National Library of Medicine, August 2007.Accessed February 18, 2014.
13. Martelli A, Santos AR Jr [2014] Cellular and morphological aspects of fibrodysplasia ossificans progressive . Lessons of formation, repair, and bone bioengineering. Organogenesis [Review] 10: 303-311.
14. Kasper, DL, Fauci AS, Longo DL, et al. [2005] eds. Harrison’s Principles of Internal Medicine. 16thed. McGraw-Hill Companies. New York NY 2286.
15. Martelli, Anderson; Santos, Arnaldo Rodrigues [3 July 2014]. "Cellular and morphological aspects of fibrodysplasia ossificans progressiva: Lessons of formation, repair, and bone bioengineering". Organogenesis. 10 [3]: 303–311.
16. Maiti D, Shilpa NM. " Stone Man Syndrome: A Rare and Debilitating Genetic Disorder with a Misguided Immune Response.
17. Allen RS, Tajer B, Shore EM, Mullins MC. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish. Elife. 2020 Sep 8;9:e53761.
18. José Antonio Valer, Cristina Sánchez-de-Diego, Carolina Pimenta-Lopes, Jose Luis Rosa and Francesc Ventura. ACVR1 Function in Health and Disease. Cells 2019;8:1366-92. doi:10.3390/cells8111366
19. Kohei Miyazono, Tomomasa Shimanuki. Bone Morphogenetic Protein Receptors and Actions. Principles of Bone Biology 2008; 3:1177-97
20. Kristi Wharton, Rik Derynck. TGFβ family signaling: novel insights in development and disease. Development 2009;136:3691-7.doi:10.1242/dev.040584
21. Guiqian Chen, Chuxia Deng, Yi-Ping Li. TGF-β and BMP Signaling in Osteoblast Differentiation and Bone Formation. International Journal of Biological Sciences 2012; 8[2]:272- 88. doi: 10.7150/ijbs.2929
22. Asadi S, Aranian MR. The Role of Genetics Mutations in Genes ACVR1, BMPR1A, BMPR1B, BMPR2, BMP4 in Stone Man Syndrome. J Hematol Hemother 5: 008.
23. Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics. 2008;121[5]:e1295- 300.
24. Shore EM, Kaplan FS. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva. Curr Osteoporos Rep. 2011;9[2]:83-8
25. Delai PLR, Kantanie S, Santili C, et al. Fibrodysplasia ossificans progressiva: a hereditary illness of multidisciplinary interest. Rev Bras Ortop. 2004;39[4]:205-13.
26. Mahboubi S, Glaser DL, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva. Pediatr Radiol. 2001;31[5]:307-14.
27. Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva [FOP] phenotypes are caused by mutations in the bone morphogenetic protein [BMP] type I receptor ACVR1. Hum Mutat. 2009;30[3]:379-90.

28. Baujat G, Choquet R, Bouée S, et al. Prevalence of fibrodysplasia ossificans progressiva [FOP] in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12[1]:123.
29. Kaplan FS, Shore EM. Perspective: progressive osseous heteroplasia. J Bone Miner Res. 2000;15[11]:2084-94.
30. Pignolo RJ, Durbin-Johnson BP, Rocke DM, Kaplan FS. Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva [FOP]. Bone. 2020;140:115549.
31. Wang H, Lindborg C, Lounev V, et al. Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. J Bone Miner Res. 2016;31[9]:1652-65.
32. Kaplan FS, Murray JE, Sylvester JE, et al. The ethical imperative to treat rare disorders: principles and guidelines for managing fibrodysplasia ossificans progressiva. Bone. 2018;109:282-4
33. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis and management. Curr Osteoporos Rep. 2013;11[2]:179-86.
34. Kaplan FS, Al Mukaddam M, Baujat G, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2019;1:1-111.
35. Kaplan FS, Pignolo RJ, Al Mukaddam M. Bone morphogenetic protein signaling inhibition for the treatment of fibrodysplasia ossificans progressiva. Curr Osteoporos Rep. 2016;14[5]:169-75.
36. Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2019;85[6]:1180-7.
37. Kaplan FS, Al Mukaddam M, Shore EM. Therapeutic approaches to fibrodysplasia ossificans progressiva. Bone. 2018;109:247-55.
38. Chakkalakal SA, Uchibe K, Convente MR, et al. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1R206H fibrodysplasia ossificans progressiva [FOP] mutation. J Bone Miner Res. 2016;31[9]:1666-75.
39. Haviv R, Moshe V, De Benedetti F, et al. A novel therapeutic approach for fibrodysplasia ossificans progressiva using IL1β receptor antagonist. J Bone Miner Res. 2019;34[9]:1657-66.
40. Kaplan FS, Al Mukaddam M, Pignolo RJ. Acute and chronic care considerations for patients with fibrodysplasia ossificans progressiva. Curr Osteoporos Rep. 2020;18[5]:531-40.
41. Connor JM, Evans DA. Genetic aspects of fibrodysplasia ossificans progressiva. J Med Genet. 1982;19[1]:35-9.
42. Pignolo RJ, Bedford-Gay C, Liljesthröm M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva: a comprehensive global assessment. J Bone Miner Res. 2016;31[3]:650-6.
43. Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92[3]:686-91.
44. Hsiao EC, Di Rocco M, Cali A, et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva [FOP]. Br J Clin Pharmacol. 2019;85[6]:1199-207.
45. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80.
46. Kaplan FS, Al Mukaddam M, Pignolo RJ. Emergency care of patients with fibrodysplasia ossificans progressiva. Muscle Nerve. 2019;59[4]:397-403.
47. Kaplan FS, Al Mukaddam M, Pignolo RJ. A cumulative analogue joint involvement scale [CAJIS] for fibrodysplasia ossificans progressiva [FOP]. Bone. 2017;101:123-8.
48. Mantick N, Bachman E, Baujat G, et al. The FOP connection registry: Design of an international patient-sponsored registry for fibrodysplasia ossificans progressiva. Bone. 2018;109:285-90.
49. Shore EM, Kaplan FS. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva [FOP]. Bone. 2008;43[3]:427-33.